Oppenheimer raised the firm’s price target on Palvella Therapeutics (PVLA) to $120 from $100 and keeps an Outperform rating on the shares.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVLA:
- Palvella Therapeutics reports Q3 EPS ($1.03), consensus (84c)
- Palvella Therapeutics Reports Q3 2025 Financial Results
- PVLA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Palvella Therapeutics price target raised to $110 from $73 at Chardan
- Palvella Therapeutics price target raised to $97 from $65 at TD Cowen